SYDNEY, AU, Feb 3, 2023 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy […]
HONG KONG, Oct 20, 2022 – (ACN Newswire via SEAPRWire.com) – VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as “VectorBuilder”), a top gene delivery enterprise, recently announced the completion […]
SYDNEY, AU, Sep 15, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award […]
HONG KONG, Apr 24, 2022 – (ACN Newswire via SEAPRWire.com) – Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital’s co-founded company Innostellar Biotherapeutics, announced that the clinical trial […]
SHENZHEN, CHINA, Sep 16, 2021 – (ACN Newswire via SEAPRWire.com) – At 6 p.m. on September 8 UTC+8, the GENE TREE Technology Sharing Online Roundtable with the theme of “Exploration […]
TOKYO, Aug 16, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor “Tazverik Tablets 200 mg” (tazemetostat hydrobromide), […]
TOKYO, Jun 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor “Tazverik Tablets 200 […]
